Online inquiry

IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15565MR)

This product GTTS-WQ15565MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15565MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11213MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ1721MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ4205MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ8647MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ4005MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ7410MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW